ClinicalTrials.gg
RecruitingNCT04559425Updated May 22, 2024

Slow Heart Registry of Fetal Immune-mediated High Degree Heart Block

An observational study in Heart Block Complete and Heart Block Second Degree, sponsored by The Hospital for Sick Children. Recruiting at 27 sites in 12 countries. Open to female participants aged 16 Years to 50 Years. Per ClinicalTrials.gov, last updated 2024-05-22.

Sponsored by The Hospital for Sick Children · Observational

How we know

From the registry’s dates

  • Started Jan 2020; still recruiting 6 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
350
Ages
16 Years to 50 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Heart Block with a site in United States — 5 open to participants now, 5 under way, none of them phase 3. Heart Block · United States.

Started
2020
with 1 other
Observational
7 of 13
3 open now
Registered
6th of 13
by date

Among the 13 studies in Heart Block with a site in United States, this one is one of 2 that started in 2020, is one of 7 observational ones, and was the 6th registered.

Heart Block

39 studies on the registry are indexed under Heart Block; 12 are open to participants now.

Browse Heart Block studies →

Open to participants now

5 of the 13 studies in Heart Block with a site in United States are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 10 Heart Block studies recruiting now, 7 (70%) set no upper age limit and 1 (10%) stops at 75 or younger; 2 take children under 18; none take healthy volunteers.

This study: 16 Years to 50 Years · female.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Heart Block with a site in United States, or all of them as a file.
02

Study summary

Few studies are specifically designed to address health concerns that are already relevant during pregnancy. The consequence is a lack of evidence on best clinical practice. This includes mothers and their babies when pregnancy is complicated by an abnormally slow heart rate due to maternal antibody-mediated heart disease in the unborn baby (fetus). Since the late seventies, it has been possible to detect and monitor fetal disease by ultrasound images and to treat selected conditions with pharmaceuticals administered via the mother. To this day, physicians need to make decisions about the management of such pregnancies without evidence from prospective clinical trials on drug efficacy and safety. The SLOW HEART REGISTRY is a multi-centered prospective observational study that will address the knowledge gap to guide future management of high-degree immune-mediated heart block to the best of care. The study seeks to establish an international database of the management and outcome of affected fetuses, to be used to publish information on the results of currently available prenatal care and to evaluate the need for additional research.

Read the detailed description

The SLOW HEART REGISTRY is a multi-centered prospective observational study of fetuses diagnosed with high-degree immune-mediated atrio-ventricular heart block (AVB). The study seeks to establish an international database of the management and outcome of affected fetuses, to be used to publish information on the results of currently available prenatal care and to evaluate the need for additional research.

The study aims are to document the outcome of patients diagnosed prenatally with immune-mediated 2nd or 3rd degree AVB irrespective of the primary choice of prenatal care.

The primary objective will be to determine the rate of transplant-free survival to 1 year of life of fetuses with AVB based on the prenatal management decision:

  • Cohort 1: Fetuses not treated with fluorinated glucocorticoids
  • Cohort 2: Fetuses treated with fluorinated glucocorticoids from the time of immune-mediated AVB diagnosis.

Secondary objectives will be to determine:

  1. the evolution of clinical findings from AVB diagnosis to birth (AV conduction; fetal heart rate; other NL manifestations; fetal growth; effusions/hydrops) between cohorts;
  2. the need of new/additional treatment (steroids; beta-mimetics; IVIG) to birth;
  3. gestational age and weight at birth;
  4. postnatal management (pacing; steroids; IVIG); and
  5. clinical evolution from birth to 1-3 years of life (cardiac function; developmental milestones; infant growth; health).

Prevalence of relevant fetal-maternal events and complications (death; IUGR; morbidity) between the study cohorts will also be determined.

All management is decided by the treating center and physicians in accordance to institutional guidelines and clinical findings. Patient enrollment in the SLOW HEART REGISTRY is possible within up to 8 days of the initial management decision.

Participation in this prospective observational cohort study requires site REB approval and an executed legal contract with the primary investigator/SickKids Hospital, Toronto.

03

Conditions studied

  • Heart Block Complete
  • Heart Block Second Degree

Browse trials for

Keywords

  • fetal
  • heart block
  • anti-Ro antibodies
  • steroids
  • outcome
04

Who can participate

Ages eligible
16 Years to 50 Years
Sexes eligible
Female
Sampling method
Probability sample

Study population

Enrollment into the SLOW HEART Registry is possible within maximally 8 days of the fetal heart block diagnosis and a management decision to treat or not to treat. If a mother elects participation in the Registry, her treating physician will continue to provide care in accordance with clinical practice at the site and will decide all therapy including close observation without or with immediate steroid treatment.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written informed maternal consent to participate in the Slow Heart Registry
  • High-degree (2nd; 2:1; 2nd-3rd or 3rd degree) AVB diagnosed ≤ 32+0 weeks with or without hydrops
  • Enrollment within maximally 8 days of high-degree AVB diagnosis
  • Positive or pending anti-Ro/La antibody test results at the time of enrollment

Exclusion criteria

Exclusion Criteria:

  • AVB associated with major CHD (e.g. left atrial isomerism, cc-TGA)
  • AVB with known negative anti-Ro and/or La antibody test result at enrollment
  • 1st degree AVB
  • Sinus bradycardia with normal 1:1 AV conduction
  • Blocked atrial bigeminy (irregular atrial rate with failure of AV conduction of the premature atrial beat)
  • Primary delivery for postnatal treatment
  • Maternal-fetal conditions (other than cardiac NL) associated with high odds of premature delivery or death (e.g. renal failure, significant infectious diseases, major extracardiac anomalies, PROM, etc.)
  • Preexisting maternal mental disorder (e.g. bipolar, mania, severe depression, substance abuse)
  • Poorly controlled insulin-dependent diabetes ( >7%) at CAVB diagnosis
  • Oligohydramnios (deepest/maximal vertical pocket \<2 cm)
  • Severe IUGR (estimated fetal weight \<3rd percentile)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
350 participants (estimated)
Target follow-up
36 Months
Patient registry
Yes

Groups and cohorts

  • Prospective observational cohort 1

    Complete AVB (3rd degree) diagnosed ≤ 32+0 weeks with or without hydrops

    Drug: Dexamethasone · Other: No Dexamethasone

  • Prospective observational cohort 2

    Incomplete AVB (2nd; 2:1; 2nd-3rd degree) diagnosed ≤ 32+0 weeks with or without hydrops

    Drug: Dexamethasone · Other: No Dexamethasone

Interventions

  • All management decisions are made by the primary physician and may include: 1) no treatment with dexamethasone or 2) treatment with dexamethasone from the time of enrollment

  • OtherNo Dexamethasone

    All management decisions are made by the primary physician and may include: 1) no treatment with dexamethasone or 2) treatment with dexamethasone from the time of enrollment

06

What researchers measure

Primary outcomes

  1. Freedom from cardiac death ≥1 year of life

    Time frame: up to 12 months

Secondary outcomes

  1. Proportion of participants with fetal and neonatal death and their causes/factors

    Time frame: 1 month

  2. Proportion of participants with change in prenatal treatment

    Time frame: up to 6 months

  3. Proportion of secondarily treated patients (initially untreated group 1 cases)

    Time frame: up to 6 months

  4. Proportion of serious pregnancy outcomes (IUFD, IUGR <3rd percentile, delivery <35 weeks)

    Time frame: up to 6 months

  5. Proportion of patients/group with progression from incomplete to complete AVB by 1 year

    Time frame: Fetal diagnosis to 12 months

  6. Proportion of maternal serious adverse events and outcomes

    Time frame: Fetal diagnosis to 12 months

  7. Average gestational age at birth

    Time frame: Birth

  8. Average birth weight

    Time frame: Birth

  9. Freedom from permanent pacemaker implantation from birth to 1 year of life

    Time frame: Birth to 12 months

  10. Prevalence of significant heart failure (HF score, echo, HF treatment) at 1 year of life

    Time frame: 12 months

  11. Proportion of children with moderate/severe neuro-developmental delay at 12-18 months

    Time frame: 12-18 months

07

Study locations

27 of 27 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2020 (actual). Primary completion is estimated for Dec 2027, 95 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2020
First posted
Sep 22, 2020
StartActual
Jan 1, 2020
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2029
Last update
May 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04559425
Responsible party
Edgar Jaeggi (Senior Associate Scientist Emeritus, The Hospital for Sick Children) — Principal investigator
First posted
Sep 22, 2020
Start date
Jan 1, 2020
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
May 22, 2024

Study contacts

Diana Balmer-Minnes, BSc, CCRP
Contact
slow.heart@sickkids.ca
416-813-7654 ext. 228624
Edgar Jaeggi, MD
Contact
slow.heart@sickkids.ca
418-813-7466
Edgar Jaeggi, MD
principal investigator · The Hospital for Sick Children, Toronto

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion